YishengBio

The company's business model centers on generating revenue from its commercialized products while advancing a pipeline of new candidates. Its primary revenue stream comes from the YSJA™ rabies vaccine, which is a leading product in China. Since its production launch in 2020, over 19.9 million doses have been sold to more than 1,687 county-level Centers for Disease Control and Prevention (CDCs) in China as of March 2023. The company operates on a global scale, with a corporate structure that includes a holding company in the Cayman Islands and subsidiaries in China, the U.S., Singapore, and the Philippines. In March 2023, YS Biopharma went public on the Nasdaq through a merger with Summit Healthcare Acquisition Corp., a special purpose acquisition company (SPAC), which was expected to provide approximately $36 million in gross proceeds to fund clinical development and commercialization.

At the core of its research and development is the proprietary PIKA® immunomodulating technology platform. This platform utilizes a synthetic dsRNA complex that activates the immune system through TLR3, RIG-I, and MDA-5 signaling pathways to induce a prompt production of interferons and cytokines. This technology forms the basis for a new generation of vaccines and therapeutics designed to offer improved treatments for viral infections and cancer. The product pipeline includes several clinical-stage candidates, such as the PIKA rabies vaccine, which aims to provide faster protection with a one-week regimen compared to the conventional three or four-week schedules. Other candidates in development target Hepatitis B, COVID-19, and various cancers.